Company / Accounts Receivable
Omnicell Accounts Receivable History
FY2016-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$196.2M
FY2018
5-year range
-
FY2016-FY2018
Trend
+3.3%
vs FY2017
Sector context
#72 of 138
Health Care
What the data says
At $196M, Omnicell's accounts receivable ranks #72 of 138 in the Health Care sector. Improved from $150M to $196M over the past 2 years.
Based on SEC 10-K filings.
$196M in FY2018.
Improved from $150M to $196M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#72 of 138 in Health CareTop 52% of 138This company $196.2M Sector average $1.3B
▼
-85.1% below sector average
Key checks
Key Insights
- In FY2018, accounts receivable increased 3.3% year-over-year.
- Ranks #72 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $196.2M | +3.3% |
| FY2017 | $190.0M | +26.4% |
| FY2016 | $150.3M | +39.2% |
As of FY2018 · SEC 10-K · Updated Jun 30, 2026